Table 1.
Participating centers: international cohort study of malignancy in SLE
| Center | n* | Cohort assembly | Inclusion |
|---|---|---|---|
| NORTH AMERICA | |||
| Baltimore, MD, USA | 1691 | Followed from first clinic visit¶ | ACR criteria‡ |
| Pittsburgh, PA, USA | 1587 | University of Pittsburgh/regional rheumatology | ACR criteria‡ |
| Toronto, ON, Canada | 1316 | Followed from first clinic visit† | ACR criteria‡ |
| Downstate University–Brooklyn, NY, USA | 1124 | Followed from first clinic visit† | ACR criteria‡ |
| San Francisco, CA, USA | 721 | Lupus Outcomes Study cohort | ACR criteria‡ |
| Los Angeles, CA, USA | 655 | Followed from first clinic visit¶ | ACR criteria‡ |
| Chicago, IL, USA | 598 | Followed from first clinic visit¶ | ACR criteria |
| Calgary, AB, Canada | 522 | Enrolled from regional physician network† | ACR criteria‡ |
| Montreal General Hospital, QC, Canada | 499 | Followed from first clinic visit† | ACR criteria |
| Winnipeg, MB, Canada | 402 | Followed from first clinic visit§ | ACR criteria‡ |
| Chapel Hill, NC, USA | 357 | Followed from first clinic visit¶ | ACR criteria‡ |
| South Carolina, USA | 351 | Followed from first clinic visit | ACR criteria |
| Saskatoon, SK, Canada | 306 | Followed from first clinic visit | ACR criteria‡ |
| Birmingham, AL, USA | 298 | Inception cohort (consenting to linkage)† | ACR criteria |
| Albert Einstein University, NYC, USA | 240 | Followed from first clinic visit§ | ACR criteria‡ |
| Halifax, NS, Canada | 232 | Followed from first clinic visit† | ACR criteria |
| Notre-Dame Hospital, Montreal, QC, Canada | 121 | Followed from first clinic visit¶ | ACR criteria |
| Hôpital Maisonneuve-Rosemont Montreal, QC | 120 | Hospital discharge and clinic records§ | ACR criteria‡ |
| London, Ontario, Canada | 90 | Followed from first clinic visit§ | ACR criteria‡ |
| Vancouver, BC, Canada | 81 | Followed from first clinic visit§ | ACR criteria‡ |
| New York University, NYC, USA | 78 | Followed from first clinic visit | ACR criteria |
| UNITED KINGDOM | |||
| Lanarkshire, Scotland | 1937 | Hospital discharge registry§ | Discharge# |
| Birmingham, England | 439 | Followed from first clinic visit† | ACR criteria |
| London, England | 273 | Followed from first clinic visit† | ACR criteria‡ |
| OTHER CENTERS | |||
| Seoul, Korea | 770 | Followed from first clinic visit† | ACR criteria‡ |
| Copenhagen, Denmark | 560 | Followed from first clinic visit† | ACR criteria‡ |
| Barakoldo, Spain | 298 | Followed from first clinic visit† | ACR criteria‡ |
| Lund, Sweden | 282 | Inception cohort, enroll at SLE diagnosis | ACR criteria |
| Hannover, Germany | 240 | Followed from first clinic visit† | ACR criteria‡ |
| Reykjavik, Iceland | 221 | Unselected patients from national registry¶ | ACR criteria |
| TOTAL | 16,409 | ||
*
Number of subjects at each center corresponds to those present during the time in which cancer registry data were available.
†
Prospective assembly.
‡
At least 95% of cohort members met 4 components of the American College of Rheumatology (ACR) diagnostic criteria for SLE (18, 19); patients with a clinical diagnosis of SLE but meeting <4 ACR criteria were not excluded.
§
Retrospective assembly.
†
Retrospective and prospective assembly.
#
Any hospital discharge diagnosis of SLE, primary, or non-primary. Cohort entry was date of first discharge with SLE diagnosis